SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rai, K. R. Articles by Pasternack, B. S. Search for Related Content PubMed PubMed Citation Articles by Rai, K. R. Articles by Pasternack, B. S. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Clinical staging of chronic lymphocytic leukemia KR Rai, A Sawitsky, EP Cronkite, AD Chanana, RN Levy and BS Pasternack A method of clinical staging of chronic lymphocytic leukemia (CLL) has been proposed which is based on the concept that CLL is a disease of progressive accumulation of nonfunctioning lymphocytes: stage O, bone marrow and blood lymphocytosis only; stage 1, lymphocytosis with enlarged nodes; stage II, lymphocytosis with enlarged spleen or liver or both; stage III, lymphocytosis with anemia; and stage IV:lymphocytosis with thrombocytopenia. Analysis of 125 patients. in the present series showed the following median survival times (in months) from diagnosis: stage 0, is greater than 150; stage I 101; stage II, 71; stage III, 19; stage IV, 19, The median survival for the entire series was 71 mo. The prognostic significance of the stage remained even after adjustment was made for age and sex. However, both sex and age were shown to be poor predictors of survival after adjustment for stage. The method of staging proved to be a reliable predictor of survival whether used at diagnosis or during the course of the disease. The proposed staging system was an equally accurate indicator for survival when applied to two other previously published studies of large series of patients Volume 46, Issue 2, pp. 219-234, 08/01/1975 Copyright © 1975 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Sharma and A. Lichtenstein Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells Blood, November 5, 2009; 114(19): 4179 - 4185. [Abstract] [Full Text] [PDF] B. F. Eichhorst, R. Busch, S. Stilgenbauer, M. Stauch, M. A. Bergmann, M. Ritgen, N. Kranzhofer, R. Rohrberg, U. Soling, O. Burkhard, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood, October 15, 2009; 114(16): 3382 - 3391. [Abstract] [Full Text] [PDF] J. Delgado, D. W. Milligan, and P. Dreger Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Blood, September 24, 2009; 114(13): 2581 - 2588. [Abstract] [Full Text] [PDF] A. Vlad, P.-A. Deglesne, R. Letestu, S. Saint-Georges, N. Chevallier, F. Baran-Marszak, N. Varin-Blank, F. Ajchenbaum-Cymbalista, and D. Ledoux Down-regulation of CXCR4 and CD62L in Chronic Lymphocytic Leukemia Cells Is Triggered by B-Cell Receptor Ligation and Associated with Progressive Disease Cancer Res., August 15, 2009; 69(16): 6387 - 6395. [Abstract] [Full Text] [PDF] P. Caprino, M. P. Ridolfini, S. Berardi, L. Sofo, and D. D'Ugo Image of the Month--Quiz Case Arch Surg, August 1, 2009; 144(8): 783 - 783. [Full Text] [PDF] M. C. Bene and J. S. Kaeda How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet Haematologica, August 1, 2009; 94(8): 1135 - 1150. [Abstract] [Full Text] [PDF] I. Del Giudice, S. Chiaretti, S. Tavolaro, M. S. De Propris, R. Maggio, F. Mancini, N. Peragine, S. Santangelo, M. Marinelli, F. R. Mauro, et al. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases Blood, July 16, 2009; 114(3): 638 - 646. [Abstract] [Full Text] [PDF] R. Chen, W. G. Wierda, S. Chubb, R. E. Hawtin, J. A. Fox, M. J. Keating, V. Gandhi, and W. Plunkett Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia Blood, May 7, 2009; 113(19): 4637 - 4645. [Abstract] [Full Text] [PDF] T. N. Hartmann, V. Grabovsky, W. Wang, P. Desch, G. Rubenzer, S. Wollner, I. Binsky, A. Vallon-Eberhard, A. Sapoznikov, M. Burger, et al. Circulating B-Cell Chronic Lymphocytic Leukemia Cells Display Impaired Migration to Lymph Nodes and Bone Marrow Cancer Res., April 1, 2009; 69(7): 3121 - 3130. [Abstract] [Full Text] [PDF] V. Grubor, A. Krasnitz, J. E. Troge, J. L. Meth, B. Lakshmi, J. T. Kendall, B. Yamrom, G. Alex, D. Pai, N. Navin, et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA) Blood, February 5, 2009; 113(6): 1294 - 1303. [Abstract] [Full Text] [PDF] J. BOELENS, S. LUST, B. VANHOECKE, and F. OFFNER Chronic Lymphocytic Leukaemia Anticancer Res, February 1, 2009; 29(2): 605 - 615. [Abstract] [Full Text] [PDF] E. J. Lewintre, C. R. Martin, C. G. Ballesteros, D. Montaner, R. F. Rivera, J. R. Mayans, and J. Garcia-Conde Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia Haematologica, February 1, 2009; 94(2): 280 - 284. [Abstract] [Full Text] [PDF] R. Sargent, D. Jones, L. V. Abruzzo, H. Yao, J. Bonderover, M. Cisneros, W. G. Wierda, M. J. Keating, and R. Luthra Customized Oligonucleotide Array-Based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia J. Mol. Diagn., January 1, 2009; 11(1): 25 - 34. [Abstract] [Full Text] [PDF] T. J. Kipps Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy ASCO Educational Book, January 1, 2009; 2009(1): 385 - 393. [Abstract] [Full Text] [PDF] G. V. Hegde, K. J. Peterson, K. Emanuel, A. K. Mittal, A. D. Joshi, J. D. Dickinson, G. J. Kollessery, R. G. Bociek, P. Bierman, J. M. Vose, et al. Hedgehog-Induced Survival of B-Cell Chronic Lymphocytic Leukemia Cells in a Stromal Cell Microenvironment: A Potential New Therapeutic Target Mol. Cancer Res., December 1, 2008; 6(12): 1928 - 1936. [Abstract] [Full Text] [PDF] L. Trentin, M. Frasson, A. Donella-Deana, F. Frezzato, M. A. Pagano, E. Tibaldi, C. Gattazzo, R. Zambello, G. Semenzato, and A. M. Brunati Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia Blood, December 1, 2008; 112(12): 4665 - 4674. [Abstract] [Full Text] [PDF] K. J. Till, R. J. Harris, A. Linford, D. G. Spiller, M. Zuzel, and J. C. Cawley Cell Motility in Chronic Lymphocytic Leukemia: Defective Rap1 and {alpha}L{beta}2 Activation by Chemokine Cancer Res., October 15, 2008; 68(20): 8429 - 8436. [Abstract] [Full Text] [PDF] L. Kujawski, P. Ouillette, H. Erba, C. Saddler, A. Jakubowiak, M. Kaminski, K. Shedden, and S. N. Malek Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia Blood, September 1, 2008; 112(5): 1993 - 2003. [Abstract] [Full Text] [PDF] G. Dighiero Monoclonal B-Cell Lymphocytosis -- A Frequent Premalignant Condition N. Engl. J. Med., August 7, 2008; 359(6): 638 - 640. [Full Text] [PDF] J. Redondo-Munoz, E. Ugarte-Berzal, J. A. Garcia-Marco, M. H. del Cerro, P. E. Van den Steen, G. Opdenakker, M. J. Terol, and A. Garcia-Pardo {alpha}4{beta}1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells Blood, July 1, 2008; 112(1): 169 - 178. [Abstract] [Full Text] [PDF] M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood, June 15, 2008; 111(12): 5446 - 5456. [Abstract] [Full Text] [PDF] P. E. M. Patten, A. G. S. Buggins, J. Richards, A. Wotherspoon, J. Salisbury, G. J. Mufti, T. J. Hamblin, and S. Devereux CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment Blood, May 15, 2008; 111(10): 5173 - 5181. [Abstract] [Full Text] [PDF] N. Gachard, A. Salviat, C. Boutet, C. Arnoulet, F. Durrieu, B. Lenormand, S. Lepretre, S. Olschwang, F. Jardin, M. Lafage-Pochitaloff, et al. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method Haematologica, February 1, 2008; 93(2): 215 - 223. [Abstract] [Full Text] [PDF] C. Saddler, P. Ouillette, L. Kujawski, S. Shangary, M. Talpaz, M. Kaminski, H. Erba, K. Shedden, S. Wang, and S. N. Malek Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia Blood, February 1, 2008; 111(3): 1584 - 1593. [Abstract] [Full Text] [PDF] C. Visco, M. Ruggeri, M. Laura Evangelista, R. Stasi, R. Zanotti, I. Giaretta, A. Ambrosetti, D. Madeo, G. Pizzolo, and F. Rodeghiero Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia Blood, February 1, 2008; 111(3): 1110 - 1116. [Abstract] [Full Text] [PDF] V. Gattei, P. Bulian, M. I. Del Principe, A. Zucchetto, L. Maurillo, F. Buccisano, R. Bomben, M. Dal-Bo, F. Luciano, F. M. Rossi, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia Blood, January 15, 2008; 111(2): 865 - 873. [Abstract] [Full Text] [PDF] A. W. Hauswirth and U. Jager Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia Haematologica, January 1, 2008; 93(1): 14 - 19. [Full Text] [PDF] E. Domingo-Domenech, Y. Benavente, E. Gonzalez-Barca, C. Montalban, J. Guma, R. Bosch, S. S. Wang, Q. Lan, D. Whitby, A. Fernandez de Sevilla, et al. Impact of interleukin-10 polymorphisms ( 1082 and 3575) on the survival of patients with lymphoid neoplasms Haematologica, November 1, 2007; 92(11): 1475 - 1481. [Abstract] [Full Text] [PDF] A. M. Tsimberidou, S. Wen, S. O'Brien, P. McLaughlin, W. G. Wierda, A. Ferrajoli, S. Faderl, J. Manning, S. Lerner, C. V. Mai, et al. Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center J. Clin. Oncol., October 10, 2007; 25(29): 4648 - 4656. [Abstract] [Full Text] [PDF] S. Molica, M. Montillo, D. Ribatti, R. Mirabelli, A. Tedeschi, F. Ricci, S. Veronese, A. Vacca, and E. Morra Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia Haematologica, October 1, 2007; 92(10): 1367 - 1374. [Abstract] [Full Text] [PDF] B. Stamatopoulos, N. Meuleman, B. Haibe-Kains, H. Duvillier, M. Massy, P. Martiat, D. Bron, and L. Lagneaux Quantification of ZAP70 mRNA in B Cells by Real-Time PCR Is a Powerful Prognostic Factor in Chronic Lymphocytic Leukemia Clin. Chem., October 1, 2007; 53(10): 1757 - 1766. [Abstract] [Full Text] [PDF] A. D. Joshi, G. V. Hegde, J. D. Dickinson, A. K. Mittal, J. C. Lynch, J. D. Eudy, J. O. Armitage, P. J. Bierman, R. G. Bociek, M. P. Devetten, et al. ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38 Expressing B-Cell Chronic Lymphocytic Leukemia Clin. Cancer Res., September 15, 2007; 13(18): 5295 - 5304. [Abstract] [Full Text] [PDF] P. Kokhaei, A. O. Abdalla, L. Hansson, E. Mikaelsson, M. Kubbies, A. Haselbeck, H. Jernberg-Wiklund, H. Mellstedt, and A. Osterborg Expression of Erythropoietin Receptor and In vitro Functional Effects of Epoetins in B-Cell Malignancies Clin. Cancer Res., June 15, 2007; 13(12): 3536 - 3544. [Abstract] [Full Text] [PDF] P. Josefsson, C. H. Geisler, H. Leffers, J. H. Petersen, M. K. Andersen, J. Jurlander, and A. M. Buhl CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia Blood, June 1, 2007; 109(11): 4973 - 4979. [Abstract] [Full Text] [PDF] W. G. Wierda, S. O'Brien, X. Wang, S. Faderl, A. Ferrajoli, K.-A. Do, J. Cortes, D. Thomas, G. Garcia-Manero, C. Koller, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia Blood, June 1, 2007; 109(11): 4679 - 4685. [Abstract] [Full Text] [PDF] R. J. Ford, L. Shen, Y. C. Lin-Lee, L. V. Pham, A. Multani, H.-J. Zhou, A. T. Tamayo, C. Zhang, L. Hawthorn, J. K. Cowell, et al. Development of a murine model for blastoid variant mantle-cell lymphoma Blood, June 1, 2007; 109(11): 4899 - 4906. [Abstract] [Full Text] [PDF] B. F. Eichhorst, R. Busch, T. Obwandner, I. Kuhn-Hallek, P. Herschbach, and M. Hallek Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study Group J. Clin. Oncol., May 1, 2007; 25(13): 1722 - 1731. [Abstract] [Full Text] [PDF] A. Muntanola, F. Bosch, P. Arguis, E. Arellano-Rodrigo, C. Ayuso, E. Gine, M. Crespo, P. Abrisqueta, C. Moreno, F. Cobo, et al. Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic Leukemia J. Clin. Oncol., April 20, 2007; 25(12): 1576 - 1580. [Abstract] [Full Text] [PDF] E. Ocana, L. Delgado-Perez, A. Campos-Caro, J. Munoz, A. Paz, R. Franco, and J. A. Brieva The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells Haematologica, March 1, 2007; 92(3): 349 - 356. [Abstract] [Full Text] [PDF] F. Van Bockstaele, V. Pede, A. Janssens, F. Callewaert, F. Offner, B. Verhasselt, and J. Philippe Lipoprotein Lipase mRNA Expression in Whole Blood Is a Prognostic Marker in B Cell Chronic Lymphocytic Leukemia Clin. Chem., February 1, 2007; 53(2): 204 - 212. [Abstract] [Full Text] [PDF] N. E. Kay, S. M. Geyer, T. G. Call, T. D. Shanafelt, C. S. Zent, D. F. Jelinek, R. Tschumper, N. D. Bone, G. W. Dewald, T. S. Lin, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia Blood, January 15, 2007; 109(2): 405 - 411. [Abstract] [Full Text] [PDF] A. Chanan-Khan, K. C. Miller, L. Musial, D. Lawrence, S. Padmanabhan, K. Takeshita, C. W. Porter, D. W. Goodrich, Z. P. Bernstein, P. Wallace, et al. Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study J. Clin. Oncol., December 1, 2006; 24(34): 5343 - 5349. [Abstract] [Full Text] [PDF] F. Dicker, S. Schnittger, T. Haferlach, W. Kern, and C. Schoch Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression Blood, November 1, 2006; 108(9): 3152 - 3160. [Abstract] [Full Text] [PDF] T. D. Shanafelt, T. E. Witzig, S. R. Fink, R. B. Jenkins, S. F. Paternoster, S. A. Smoley, K. J. Stockero, D. M. Nast, H. C. Flynn, R. C. Tschumper, et al. Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia J. Clin. Oncol., October 1, 2006; 24(28): 4634 - 4641. [Abstract] [Full Text] [PDF] J. D. Roberts, M. R. Smith, E. J. Feldman, L. Cragg, M. M. Millenson, G. J. Roboz, C. Honeycutt, R. Thune, K. Padavic-Shaller, W. H. Carter, et al. Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. Clin. Cancer Res., October 1, 2006; 12(19): 5809 - 5816. [Abstract] [Full Text] [PDF] T. D. Shanafelt, J. C. Byrd, T. G. Call, C. S. Zent, and N. E. Kay Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med, September 19, 2006; 145(6): 435 - 447. [Abstract] [Full Text] [PDF] S. Deaglio, T. Vaisitti, S. Aydin, E. Ferrero, and F. Malavasi In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia Blood, August 15, 2006; 108(4): 1135 - 1144. [Abstract] [Full Text] [PDF] K. W. L. Yee and S. M. O'Brien Chronic Lymphocytic Leukemia: Diagnosis and Treatment Mayo Clin. Proc., August 1, 2006; 81(8): 1105 - 1129. [Abstract] [Full Text] [PDF] M. I. Del Principe, G. Del Poeta, F. Buccisano, L. Maurillo, A. Venditti, A. Zucchetto, R. Marini, P. Niscola, M. A. I. Consalvo, C. Mazzone, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia Blood, August 1, 2006; 108(3): 853 - 861. [Abstract] [Full Text] [PDF] T. Robak, J. Z. Blonski, J. Gora-Tybor, K. Jamroziak, J. Dwilewicz-Trojaczek, A. Tomaszewska, L. Konopka, B. Ceglarek, A. Dmoszynska, M. Kowal, et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2) Blood, July 15, 2006; 108(2): 473 - 479. [Abstract] [Full Text] [PDF] S. Siegel, A. Wagner, B. Friedrichs, A. Wendeler, L. Wendel, D. Kabelitz, J. Steinmann, A. Barsoum, J. Coggin, J. Rohrer, et al. Identification of HLA-A*0201-Presented T Cell Epitopes Derived from the Oncofetal Antigen-Immature Laminin Receptor Protein in Patients with Hematological Malignancies. J. Immunol., June 1, 2006; 176(11): 6935 - 6944. [Abstract] [Full Text] [PDF] A.-M. Tsimberidou, S. O'Brien, I. Khouri, F. J. Giles, H. M. Kantarjian, R. Champlin, S. Wen, K.-A. Do, S. C. Smith, S. Lerner, et al. Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation J. Clin. Oncol., May 20, 2006; 24(15): 2343 - 2351. [Abstract] [Full Text] [PDF] I. Hus, M. Podhorecka, A. Bojarska-Junak, J. Rolinski, M. Schmitt, M. Sieklucka, E. Wasik-Szczepanek, and A. Dmoszynska The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia Ann. Onc., April 1, 2006; 17(4): 683 - 690. [Abstract] [Full Text] [PDF] A. Krober, J. Bloehdorn, S. Hafner, A. Buhler, T. Seiler, D. Kienle, D. Winkler, M. Bangerter, R. F. Schlenk, A. Benner, et al. Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia J. Clin. Oncol., February 20, 2006; 24(6): 969 - 975. [Abstract] [Full Text] [PDF] A. J. Novak, D. M. Grote, S. C. Ziesmer, M. P. Kline, M. K. Manske, S. Slager, T. E. Witzig, T. Shanafelt, T. G. Call, N. E. Kay, et al. Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders J. Clin. Oncol., February 20, 2006; 24(6): 983 - 987. [Abstract] [Full Text] [PDF] B. F. Eichhorst, R. Busch, G. Hopfinger, R. Pasold, M. Hensel, C. Steinbrecher, S. Siehl, U. Jager, M. Bergmann, S. Stilgenbauer, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia Blood, February 1, 2006; 107(3): 885 - 891. [Abstract] [Full Text] [PDF] J.-L. Binet, F. Caligaris-Cappio, D. Catovsky, B. Cheson, T. Davis, G. Dighiero, H. Dohner, M. Hallek, P. Hillmen, M. Keating, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia Blood, February 1, 2006; 107(3): 859 - 861. [Abstract] [Full Text] [PDF] J. C. Byrd, J. G. Gribben, B. L. Peterson, M. R. Grever, G. Lozanski, D. M. Lucas, B. Lampson, R. A. Larson, M. A. Caligiuri, and N. A. Heerema Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy J. Clin. Oncol., January 20, 2006; 24(3): 437 - 443. [Abstract] [Full Text] [PDF] E. Montserrat New Prognostic Markers in CLL Hematology, January 1, 2006; 2006(1): 279 - 284. [Abstract] [Full Text] [PDF] B. L. Abbott Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment Oncologist, January 1, 2006; 11(1): 21 - 30. [Abstract] [Full Text] [PDF] A. Chanan-Khan, K. C. Miller, K. Takeshita, A. Koryzna, K. Donohue, Z. P. Bernstein, A. Mohr, D. Klippenstein, P. Wallace, J. B. Zeldis, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL) Blood, November 15, 2005; 106(10): 3348 - 3352. [Abstract] [Full Text] [PDF] R. Marasca, R. Maffei, M. Morselli, P. Zucchini, I. Castelli, S. Martinelli, M. Fontana, S. Ravanetti, M. Curotti, G. Leonardi, et al. Immunoglobulin Mutational Status Detected through Single-Round Amplification of Partial VH Region Represents a Good Prognostic Marker for Clinical Outcome in Chronic Lymphocytic Leukemia J. Mol. Diagn., November 1, 2005; 7(5): 566 - 574. [Abstract] [Full Text] [PDF] P. Oppezzo, Y. Vasconcelos, C. Settegrana, D. Jeannel, F. Vuillier, M. Legarff-Tavernier, E. Y. Kimura, S. Bechet, G. Dumas, M. Brissard, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia Blood, July 15, 2005; 106(2): 650 - 657. [Abstract] [Full Text] [PDF] K. J. Till, D. G. Spiller, R. J. Harris, H. Chen, M. Zuzel, and J. C. Cawley CLL, but not normal, B cells are dependent on autocrine VEGF and {alpha}4{beta}1 integrin for chemokine-induced motility on and through endothelium Blood, June 15, 2005; 105(12): 4813 - 4819. [Abstract] [Full Text] [PDF] N. Chiorazzi, K. R. Rai, and M. Ferrarini Chronic Lymphocytic Leukemia N. Engl. J. Med., February 24, 2005; 352(8): 804 - 815. [Full Text] [PDF] J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood, February 1, 2005; 105(3): 959 - 967. [Abstract] [Full Text] [PDF] J. R. Mackey, C. M. Galmarini, K. A. Graham, A. A. Joy, A. Delmer, L. Dabbagh, D. Glubrecht, L. D. Jewell, R. Lai, T. Lang, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations Blood, January 15, 2005; 105(2): 767 - 774. [Abstract] [Full Text] [PDF] M. Hallek and On Behalf Of The German CLL Study Group Chronic Lymphocytic Leukemia (CLL): First-Line Treatment Hematology, January 1, 2005; 2005(1): 285 - 291. [Abstract] [Full Text] [PDF] E. Montserrat CLL therapy: progress at last! Blood, January 1, 2005; 105(1): 2 - 3. [Full Text] [PDF] J. C. Byrd, K. Rai, B. L. Peterson, F. R. Appelbaum, V. A. Morrison, J. E. Kolitz, L. Shepherd, J. D. Hines, C. A. Schiffer, and R. A. Larson Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood, January 1, 2005; 105(1): 49 - 53. [Abstract] [Full Text] [PDF] E. Montserrat Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systems Ann. Onc., October 1, 2004; 15(10): 1450 - 1451. [Full Text] [PDF] A. Tchirkov, C. Chaleteix, C. Magnac, Y. Vasconcelos, F. Davi, A. Michel, F. Kwiatkowski, O. Tournilhac, G. Dighiero, and P. Travade hTERT expression and prognosis in B-chronic lymphocytic leukemia Ann. Onc., October 1, 2004; 15(10): 1476 - 1480. [Abstract] [Full Text] [PDF] L. Trentin, A. Cabrelle, M. Facco, D. Carollo, M. Miorin, A. Tosoni, P. Pizzo, G. Binotto, L. Nicolardi, R. Zambello, et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas Blood, July 15, 2004; 104(2): 502 - 508. [Abstract] [Full Text] [PDF] J.-F. Rossi, A. Van Hoof, K. De Boeck, S.A. Johnson, D. Bron, C. Foussard, T.A. Lister, C. Berthou, M.H.H. Kramer, T.J. Littlewood, et al. Efficacy and Safety of Oral Fludarabine Phosphate in Previously Untreated Patients With Chronic Lymphocytic Leukemia J. Clin. Oncol., April 1, 2004; 22(7): 1260 - 1267. [Abstract] [Full Text] [PDF] I. M. Ghobrial, N. D. Bone, M. J. Stenson, A. Novak, K. E. Hedin, N. E. Kay, and S. M. Ansell Expression of the Chemokine Receptors CXCR4 and CCR7 and Disease Progression in B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mayo Clin. Proc., March 1, 2004; 79(3): 318 - 325. [Abstract] [PDF] T. D. Shanafelt and T. G. Call Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia Mayo Clin. Proc., March 1, 2004; 79(3): 388 - 398. [Abstract] [PDF] A. P. Mone, P. Huang, H. Pelicano, C. M. Cheney, J. M. Green, J. Y. Tso, A. J. Johnson, S. Jefferson, T. S. Lin, and J. C. Byrd Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells Blood, March 1, 2004; 103(5): 1846 - 1854. [Abstract] [Full Text] [PDF] T. D. Shanafelt, S. M. Geyer, and N. E. Kay Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL Blood, February 15, 2004; 103(4): 1202 - 1210. [Abstract] [Full Text] [PDF] J. C. Byrd, S. Stilgenbauer, and I. W. Flinn Chronic Lymphocytic Leukemia Hematology, January 1, 2004; 2004(1): 163 - 183. [Abstract] [Full Text] [PDF] Y. Vasconcelos, F. Davi, V. Levy, P. Oppezzo, C. Magnac, A. Michel, M. Yamamoto, O. Pritsch, H. Merle-Beral, K. Maloum, et al. Binet's Staging System and VH Genes Are Independent but Complementary Prognostic Indicators in Chronic Lymphocytic Leukemia J. Clin. Oncol., November 1, 2003; 21(21): 3928 - 3932. [Abstract] [Full Text] [PDF] A. Guarini, G. Gaidano, F. R. Mauro, D. Capello, F. Mancini, M. S. De Propris, M. Mancini, E. Orsini, M. Gentile, M. Breccia, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features Blood, August 1, 2003; 102(3): 1035 - 1041. [Abstract] [Full Text] [PDF] W. J. M. Mackus, F. N. J. Frakking, A. Grummels, L. E. Gamadia, G. J. de Bree, D. Hamann, R. A. W. van Lier, and M. H. J. van Oers Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia Blood, August 1, 2003; 102(3): 1057 - 1063. [Abstract] [Full Text] [PDF] J. L. Aron, M. R. Parthun, G. Marcucci, S. Kitada, A. P. Mone, M. E. Davis, T. Shen, T. Murphy, J. Wickham, C. Kanakry, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein Blood, July 15, 2003; 102(2): 652 - 658. [Abstract] [Full Text] [PDF] M. Crespo, F. Bosch, N. Villamor, B. Bellosillo, D. Colomer, M. Rozman, S. Marce, A. Lopez-Guillermo, E. Campo, and E. Montserrat ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia N. Engl. J. Med., May 1, 2003; 348(18): 1764 - 1775. [Abstract] [Full Text] [PDF] K. R. Rai and N. Chiorazzi Determining the Clinical Course and Outcome in Chronic Lymphocytic Leukemia N. Engl. J. Med., May 1, 2003; 348(18): 1797 - 1799. [Full Text] [PDF] J. Durig, H. Nuckel, A. Huttmann, E. Kruse, T. Holter, K. Halfmeyer, A. Fuhrer, R. Rudolph, N. Kalhori, A. Nusch, et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia Blood, April 1, 2003; 101(7): 2748 - 2755. [Abstract] [Full Text] [PDF] L. Granziero, P. Circosta, C. Scielzo, E. Frisaldi, S. Stella, M. Geuna, S. Giordano, P. Ghia, and F. Caligaris-Cappio CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes Blood, March 1, 2003; 101(5): 1962 - 1969. [Abstract] [Full Text] [PDF] P. Ghia, G. Guida, S. Stella, D. Gottardi, M. Geuna, G. Strola, C. Scielzo, and F. Caligaris-Cappio The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression Blood, February 15, 2003; 101(4): 1262 - 1269. [Abstract] [Full Text] [PDF] M.-R. Rezvany, M. Jeddi-Tehrani, H. Wigzell, A. Osterborg, and H. Mellstedt Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia Blood, February 1, 2003; 101(3): 1063 - 1070. [Abstract] [Full Text] [PDF] M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps Biology and Treatment of Chronic Lymphocytic Leukemia Hematology, January 1, 2003; 2003(1): 153 - 175. [Abstract] [Full Text] [PDF] J. C. Byrd, B. L. Peterson, V. A. Morrison, K. Park, R. Jacobson, E. Hoke, J. W. Vardiman, K. Rai, C. A. Schiffer, and R. A. Larson Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) Blood, January 1, 2003; 101(1): 6 - 14. [Abstract] [Full Text] [PDF] C.-C. Chang, J. Lorek, D. E. Sabath, Y. Li, C. R. Chitambar, B. Logan, B. Kampalath, and R. P. Cleveland Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia Blood, December 15, 2002; 100(13): 4671 - 4675. [Abstract] [Full Text] [PDF] G. Munzert, D. Kirchner, H. Stobbe, L. Bergmann, R. M. Schmid, H. Dohner, and H. Heimpel Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis Blood, November 15, 2002; 100(10): 3749 - 3756. [Abstract] [Full Text] [PDF] S. Molica, A. Vacca, D. Ribatti, A. Cuneo, F. Cavazzini, D. Levato, G. Vitelli, L. Tucci, A. M. Roccaro, and F. Dammacco Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia Blood, October 16, 2002; 100(9): 3344 - 3351. [Abstract] [Full Text] [PDF] S. Bea, A. Lopez-Guillermo, M. Ribas, X. Puig, M. Pinyol, A. Carrio, L. Zamora, F. Soler, F. Bosch, S. Stilgenbauer, et al. Genetic Imbalances in Progressed B-Cell Chronic Lymphocytic Leukemia and Transformed Large-Cell Lymphoma (Richter's Syndrome) Am. J. Pathol., September 1, 2002; 161(3): 957 - 968. [Abstract] [Full Text] [PDF] A. Krober, T. Seiler, A. Benner, L. Bullinger, E. Bruckle, P. Lichter, H. Dohner, and S. Stilgenbauer VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia Blood, July 30, 2002; 100(4): 1410 - 1416. [Abstract] [Full Text] [PDF] J. Lundin, E. Kimby, M. Bjorkholm, P.-A. Broliden, F. Celsing, V. Hjalmar, L. Mollgard, P. Rebello, G. Hale, H. Waldmann, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood, July 18, 2002; 100(3): 768 - 773. [Abstract] [Full Text] [PDF] A. Osterborg, Y. Brandberg, V. Molostova, G. Iosava, K. Abdulkadyrov, M. Hedenus, and D. Messinger Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies J. Clin. Oncol., May 15, 2002; 20(10): 2486 - 2494. [Abstract] [Full Text] [PDF] M. T. de la Fuente, B. Casanova, J. V. Moyano, M. Garcia-Gila, L. Sanz, J. Garcia-Marco, A. Silva, and A. Garcia-Pardo Engagement of {alpha}4{beta}1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine J. Leukoc. Biol., March 1, 2002; 71(3): 495 - 502. [Abstract] [Full Text] [PDF] T. J. Hamblin, J. A. Orchard, R. E. Ibbotson, Z. Davis, P. W. Thomas, F. K. Stevenson, and D. G. Oscier CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease Blood, February 1, 2002; 99(3): 1023 - 1029. [Abstract] [Full Text] [PDF]

	Copyright © 1975 by American Society of Hematology         Online ISSN: 1528-0020